A citation-based method for searching scientific literature

David Russell-Jones, Stephen Gough. Clin Endocrinol (Oxf) 2012
Times Cited: 49







List of co-cited articles
362 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
18


Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.
Carel W le Roux, Simon J B Aylwin, Rachel L Batterham, Cynthia M Borg, Frances Coyle, Vyas Prasad, Sandra Shurey, Mohammad A Ghatei, Ameet G Patel, Stephen R Bloom. Ann Surg 2006
664
12

Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass.
C Dirksen, N B Jørgensen, K N Bojsen-Møller, U Kielgast, S H Jacobsen, T R Clausen, D Worm, B Hartmann, J F Rehfeld, M Damgaard,[...]. Int J Obes (Lond) 2013
158
12

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
783
12

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
12

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
10

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
Mitsuhiro Watanabe, Sander M Houten, Chikage Mataki, Marcelo A Christoffolete, Brian W Kim, Hiroyuki Sato, Nadia Messaddeq, John W Harney, Osamu Ezaki, Tatsuhiko Kodama,[...]. Nature 2006
10

Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity.
Alice P Liou, Melissa Paziuk, Jesus-Mario Luevano, Sriram Machineni, Peter J Turnbaugh, Lee M Kaplan. Sci Transl Med 2013
577
10

The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control.
Dimitri J Pournaras, Clare Glicksman, Royce P Vincent, Shophia Kuganolipava, Jamie Alaghband-Zadeh, David Mahon, Jan H R Bekker, Mohammad A Ghatei, Stephen R Bloom, Julian R F Walters,[...]. Endocrinology 2012
256
10

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Richard E Pratley, Michael Nauck, Timothy Bailey, Eduard Montanya, Robert Cuddihy, Sebastiano Filetti, Anne Bloch Thomsen, Rie Elvang Søndergaard, Melanie Davies. Lancet 2010
423
10

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
618
10

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Matthias Eckhardt, Elke Langkopf, Michael Mark, Moh Tadayyon, Leo Thomas, Herbert Nar, Waldemar Pfrengle, Brian Guth, Ralf Lotz, Peter Sieger,[...]. J Med Chem 2007
169
8

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
435
8

DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Matteo Monami, Caterina Lamanna, Carla Maria Desideri, Edoardo Mannucci. Adv Ther 2012
138
8

Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.
Hilary E Wilson-Pérez, Adam P Chambers, Karen K Ryan, Bailing Li, Darleen A Sandoval, Doris Stoffers, Daniel J Drucker, Diego Pérez-Tilve, Randy J Seeley. Diabetes 2013
194
8

Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion.
Margaret A Stefater, Darleen A Sandoval, Adam P Chambers, Hilary E Wilson-Pérez, Susanna M Hofmann, Ronald Jandacek, Patrick Tso, Stephen C Woods, Randy J Seeley. Gastroenterology 2011
71
8

Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task.
Alexander D Miras, Robert N Jackson, Sabrina N Jackson, Anthony P Goldstone, Torsten Olbers, Timothy Hackenberg, Alan C Spector, Carel W le Roux. Am J Clin Nutr 2012
94
8

Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers.
Jean-Pierre Furet, Ling-Chun Kong, Julien Tap, Christine Poitou, Arnaud Basdevant, Jean-Luc Bouillot, Denis Mariat, Gérard Corthier, Joël Doré, Corneliu Henegar,[...]. Diabetes 2010
687
8

Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids.
Rohit Kohli, David Bradley, Kenneth D Setchell, J Christopher Eagon, Nada Abumrad, Samuel Klein. J Clin Endocrinol Metab 2013
187
8

GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)?
Moahad S Dar, William H Chapman, John R Pender, Almond J Drake, Kevin O'Brien, Robert J Tanenberg, G Lynis Dohm, Walter J Pories. Obes Surg 2012
58
8

Gut hormone PYY(3-36) physiologically inhibits food intake.
Rachel L Batterham, Michael A Cowley, Caroline J Small, Herbert Herzog, Mark A Cohen, Catherine L Dakin, Alison M Wren, Audrey E Brynes, Malcolm J Low, Mohammad A Ghatei,[...]. Nature 2002
8

Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial.
Ralph Peterli, Bettina Wölnerhanssen, Thomas Peters, Noémie Devaux, Beatrice Kern, Caroline Christoffel-Courtin, Juergen Drewe, Markus von Flüe, Christoph Beglinger. Ann Surg 2009
398
8

Long-term persistence of hormonal adaptations to weight loss.
Priya Sumithran, Luke A Prendergast, Elizabeth Delbridge, Katrina Purcell, Arthur Shulkes, Adamandia Kriketos, Joseph Proietto. N Engl J Med 2011
662
8


Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism.
Mary-Elizabeth Patti, Sander M Houten, Antonio C Bianco, Raquel Bernier, P Reed Larsen, Jens J Holst, Michael K Badman, Eleftheria Maratos-Flier, Edward C Mun, Jussi Pihlajamaki,[...]. Obesity (Silver Spring) 2009
383
8

Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects.
Birgitte Sloth, Jens Juul Holst, Anne Flint, Nikolaj Ture Gregersen, Arne Astrup. Am J Physiol Endocrinol Metab 2007
157
8

Systematic review of medium-term weight loss after bariatric operations.
Paul E O'Brien, Tracey McPhail, Timothy B Chaston, John B Dixon. Obes Surg 2006
312
8

Gastric bypass reduces fat intake and preference.
Carel W le Roux, Marco Bueter, Nadine Theis, Malin Werling, Hutan Ashrafian, Christian Löwenstein, Thanos Athanasiou, Stephen R Bloom, Alan C Spector, Torsten Olbers,[...]. Am J Physiol Regul Integr Comp Physiol 2011
162
8

Human gut microbiota in obesity and after gastric bypass.
Husen Zhang, John K DiBaise, Andrea Zuccolo, Dave Kudrna, Michele Braidotti, Yeisoo Yu, Prathap Parameswaran, Michael D Crowell, Rod Wing, Bruce E Rittmann,[...]. Proc Natl Acad Sci U S A 2009
8


Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
765
8


Global estimates of the prevalence of diabetes for 2010 and 2030.
J E Shaw, R A Sicree, P Z Zimmet. Diabetes Res Clin Pract 2010
8

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
S E Inzucchi, R M Bergenstal, J B Buse, M Diamant, E Ferrannini, M Nauck, A L Peters, A Tsapas, R Wender, D R Matthews. Diabetologia 2012
975
8

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
M Pinget, R Goldenberg, E Niemoeller, I Muehlen-Bartmer, H Guo, R Aronson. Diabetes Obes Metab 2013
96
8

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Matthew C Riddle, Ronnie Aronson, Philip Home, Michel Marre, Elisabeth Niemoeller, Patrick Miossec, Lin Ping, Jenny Ye, Julio Rosenstock. Diabetes Care 2013
220
8


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
8

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
8


Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors.
Giovanni Tulipano, Valeria Sibilia, Anna Maria Caroli, Daniela Cocchi. Peptides 2011
93
6

In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins.
Aída J Velarde-Salcedo, Alberto Barrera-Pacheco, Samuel Lara-González, Gabriela M Montero-Morán, Agustín Díaz-Gois, Elvira González de Mejia, Ana P Barba de la Rosa. Food Chem 2013
78
6

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.
Hanne B Rasmussen, Sven Branner, Finn C Wiberg, Nicolai Wagtmann. Nat Struct Biol 2003
290
6

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Swenja Kröller-Schön, Maike Knorr, Michael Hausding, Matthias Oelze, Alexandra Schuff, Richard Schell, Stephan Sudowe, Alexander Scholz, Steffen Daub, Susanne Karbach,[...]. Cardiovasc Res 2012
128
6

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
6

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
6



Obesity and appetite control.
Keisuke Suzuki, Channa N Jayasena, Stephen R Bloom. Exp Diabetes Res 2012
105
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.